50270-27-4

Basic information

• Product Name: 2,4,6-TRICHLORO-PYRIMIDINE-5-CARBALDEHYDE
• Synonyms: 2,4,6-TRICHLORO-PYRIMIDINE-5-CARBALDEHYDE;2,4,6-Trichloro-5-pyrimidinecarboxaldehyde;2,4,6-Trichloropyrimidine-5-carboxaldehyde;5-Formyl-2,4,6-trichloropyrimidine;2,4,6-TrichloropyriMidin-5-carbaldehyde;5-PyriMidinecarboxaldehyde,2,4,6-trichloro-
• CAS NO: 50270-27-4
• Molecular Formula: C₅HCl₃N₂O
• Molecular Weight: 211.43324
• Product Categories: pharmacetical;Pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 50270-27-4.mol
• Article Data: 37

Chemical Properties

• Melting Point: 131-132℃
• Boiling Point: 278.592 °C at 760 mmHg
• Flash Point: 122.289 °C
• Appearance: White to brown/Solid
• Density: 1.713 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -8.75±0.39(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2,4,6-TRICHLORO-PYRIMIDINE-5-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6-TRICHLORO-PYRIMIDINE-5-CARBALDEHYDE(50270-27-4)
• EPA Substance Registry System: 2,4,6-TRICHLORO-PYRIMIDINE-5-CARBALDEHYDE(50270-27-4)

Safety Data

• RIDADR: UN2811
• HazardClass: 6.1
• Hazardous Substances Data: 50270-27-4(Hazardous Substances Data)

Usage

Uses

2,4,6-Trichloro-5-pyrimidinecarboxaldehyde is a useful reagent for organic synthesis.

Solubility

2,4,6-TRICHLORO-PYRIMIDINE-5-CARBALDEHYDE is slightly soluble in water.

InChI:InChI=1/C5HCl3N2O/c6-3-2(1-11)4(7)10-5(8)9-3/h1H

Upstream product

• 67-52-7 BARBITURIC ACID 
• 68-12-2 N,N-dimethyl-formamide 
• 67-52-7 pyrimidine-2,4,6-triol 
• 28509-24-2 tert-butylmethyl ether 

Downstream Products

• 144486-34-0 10-Methyl-8-phenylpyrido<2,3-d,6,5-d'>dipyrimidine-2,4,6(3H,7H,10H)-trione 
• 87409-76-5 4-oxo-9-methylthio-7-phenyl-3,4-dihydrothiazolo<3,4>pyrimido<5,4-e>pyrimidinium-2-oxide 
• 87624-65-5 10-Ethyl-8-phenylpyrido<2,3-d,6,5-d'>dipyrimidine-2,4,6(3H,7H,10H)-trione 
• 87624-66-6 10-Butyl-8-phenylpyrido<2,3-d,6,5-d'>dipyrimidine-2,4,6(3H,7H,10H)-trione 
• 87624-67-7 10-Octyl-8-phenylpyrido<2,3-d,6,5-d'>dipyrimidine-2,4,6(3H,7H,10H)-trione 
• 144486-36-2 10-Dodecyyl-8-phenylpyrido<2,3-d,6,5-d'>dipyrimidine-2,4,6(3H,7H,10H)-trione 
• 87624-44-0 10-Octadecyl-8-phenylpyrido<2,3-d,6,5-d'>dipyrimidine-2,4,6(3H,7H,10H)-trione 
• 343332-60-5 4-allylamino-6-benzyloxy-2-methylamino-pyrimidine-5-carbaldehyde 
• 343332-76-3 C₃₁H₄₀N₆O₉ 
• 343332-62-7 (4-allylamino-6-benzyloxy-5-formyl-pyrimidin-2-yl)-methyl-carbamic acid tert-butyl ester 
• 343332-66-1 (4-allylamino-6-benzyloxy-5-cyano-pyrimidin-2-yl)-methyl-carbamic acid tert-butyl ester 
• 343332-72-9 C₃₂H₄₂N₆O₈ 
• 343332-82-1 C₅₀H₇₂N₈O₁₂Si 
• 343332-78-5 C₅₀H₇₂N₈O₁₂Si 

Relevant articles and documents

SHP2 INHIBITORS AND USES THEREOF

Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.

Substituted pyrazole[3,4-d]pyrimidine compound as well as preparation method and application thereof

The invention discloses a substituted pyrazole[3,4-d]pyrimidine compound as well as a preparation method and application thereof. The structure of the compound is shown as a formula (I) or a formula (II). The compound provided by the invention has a good inhibition effect on phosphodiesterase type I (PDE1), and can be used as a phosphodiesterase type I inhibitor; meanwhile, a medicine prepared from the compound has a relatively good curative effect on pulmonary arterial hypertension and idiopathic pulmonary fibrosis; therefore, the compound provided by the invention has important medicinal value and wide application prospect in preparing medicines for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the compound disclosed by the invention is novel instructure, simple in preparation method and suitable for large-scale industrial production and application.

COMPOUNDS

Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis(ALS).